Abstract
Amyloid plaques, hallmark neuropathological lesions in Alzheimers disease (AD) brain, are composed of the β-amyloid peptide (Aβ). Much evidence suggests that Aβ is central to the pathophysiology of AD and is likely to play an early role in this intractable neurodegenerative disorder. Given the strong correlation between Aβ and AD, therapeutic strategies to lower cerebral Aβ levels should prove beneficial for AD treatment. Aβ is derived from amyloid precursor protein (APP) via cleavage by two proteases, β- and γ-secretase. The β-secretase has been identified as a novel aspartic protease named BACE1 (β-site APP Cleaving Enzyme 1) that initiates Aβ formation. Importantly, BACE1 appears to be dysregulated in AD. As the rate-limiting enzyme in Aβ generation, BACE1, in principle, is an excellent therapeutic target for strategies to reduce the production of Aβ in AD. While BACE1 knockout (BACE1-/-) mice have been instrumental in validating BACE1 as the authentic β-secretase in vivo, data indicates that complete abolishment of BACE1 may be associated with specific behavioral and physiological alterations. Recently a number of non-APP BACE1 substrates have been identified. It is plausible that failure to process certain BACE1 substrates may underlie some of the reported abnormalities in the BACE1-/- mice. Here we review the basic biology of BACE1, focusing on the regulation, structure and function of this enzyme. We pay special attention to the putative function of BACE1 during normal conditions and discuss in detail the relationship that exists between key risk factors for AD and the pathogenic alterations in BACE1 that are observed in the diseased state.
Keywords: β-secretase, BACE1, Alzheimer's, β-Amyloid, APP, structure, function, risk factors
Current Alzheimer Research
Title: BACE1 Structure and Function in Health and Alzheimers Disease
Volume: 5 Issue: 2
Author(s): Sarah L. Cole and Roger Vassar
Affiliation:
Keywords: β-secretase, BACE1, Alzheimer's, β-Amyloid, APP, structure, function, risk factors
Abstract: Amyloid plaques, hallmark neuropathological lesions in Alzheimers disease (AD) brain, are composed of the β-amyloid peptide (Aβ). Much evidence suggests that Aβ is central to the pathophysiology of AD and is likely to play an early role in this intractable neurodegenerative disorder. Given the strong correlation between Aβ and AD, therapeutic strategies to lower cerebral Aβ levels should prove beneficial for AD treatment. Aβ is derived from amyloid precursor protein (APP) via cleavage by two proteases, β- and γ-secretase. The β-secretase has been identified as a novel aspartic protease named BACE1 (β-site APP Cleaving Enzyme 1) that initiates Aβ formation. Importantly, BACE1 appears to be dysregulated in AD. As the rate-limiting enzyme in Aβ generation, BACE1, in principle, is an excellent therapeutic target for strategies to reduce the production of Aβ in AD. While BACE1 knockout (BACE1-/-) mice have been instrumental in validating BACE1 as the authentic β-secretase in vivo, data indicates that complete abolishment of BACE1 may be associated with specific behavioral and physiological alterations. Recently a number of non-APP BACE1 substrates have been identified. It is plausible that failure to process certain BACE1 substrates may underlie some of the reported abnormalities in the BACE1-/- mice. Here we review the basic biology of BACE1, focusing on the regulation, structure and function of this enzyme. We pay special attention to the putative function of BACE1 during normal conditions and discuss in detail the relationship that exists between key risk factors for AD and the pathogenic alterations in BACE1 that are observed in the diseased state.
Export Options
About this article
Cite this article as:
Cole L. Sarah and Vassar Roger, BACE1 Structure and Function in Health and Alzheimers Disease, Current Alzheimer Research 2008; 5 (2) . https://dx.doi.org/10.2174/156720508783954758
DOI https://dx.doi.org/10.2174/156720508783954758 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Protective Effects of Crocetin on Aβ<sub>1-42</sub>-Induced Toxicity in Ht22 Cells
CNS & Neurological Disorders - Drug Targets Introduction (Transient Receptor Potential TRP Channels as Therapeutic Drug Targets: Next Round!)
Current Topics in Medicinal Chemistry Modelling Human Disease with Pluripotent Stem Cells
Current Gene Therapy Pharmacoperones as a New Therapeutic Approach: In Vitro Identification and In vivo Validation of Bioactive Molecules
Current Drug Targets Targeting Striatal Metabotropic Glutamate Receptor Type 5 in Parkinson’s Disease: Bridging Molecular Studies and Clinical Trials
CNS & Neurological Disorders - Drug Targets Pathogenic Mechanisms and Therapeutic Strategies in Spinobulbar Muscular Atrophy
CNS & Neurological Disorders - Drug Targets Inflammasome as a New Therapeutic Target for Diabetic Complications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Mitochondrial DNA Mutations in Cancer: A Review
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Ageing (Guest Editors: H.-P. Deigner and R. Kinscherf)]
Current Drug Targets GPCR Binding Technologies: An Overview
Current Topics in Medicinal Chemistry Immunostimulatory Oligonucleotides
Recent Patents on Inflammation & Allergy Drug Discovery New Insights into Serotonin 5-HT4 Receptors : A Novel Therapeutic Target for Alzheimers Disease?
Current Alzheimer Research Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Current Neuropharmacology Membrane Permeable Lipophilic Cations as Mitochondrial Directing Groups
Current Topics in Medicinal Chemistry A New Risk Chart of Acute Myocardial Infarction in Men by an Innovative Algorithm: A Pilot Study
Current Pharmacogenomics and Personalized Medicine The Positive Synergism of CPT and MK-801 in Behavioral Tests and in Reduction of Environmental Stress and Redox Signaling Changes in Mice Cerebral Cortex
CNS & Neurological Disorders - Drug Targets Natural Products Based Ayurvedic Formulations: Chemical Cons tituents and Treatment in Neurodegenerative Disordersǂ
Mini-Reviews in Organic Chemistry Relationship between chronic disturbance of 2,3-diphosphoglycerate metabolism in erythrocytes and Alzheimer disease
CNS & Neurological Disorders - Drug Targets Chronic Stress Impacts on Olfactory System
CNS & Neurological Disorders - Drug Targets From the Editors Perspective:New Directions and New Sources for Stem Cells [Hot Topic: Stem Cells (Guest Editor: Feng C. Zhou)]
Current Neurovascular Research